The ‘Global Acute Bacterial Skin and Skin Structure Infections Treatment Market Report and Forecast 2023-2031’ by Expert Market Research gives an extensive outlook of the global acute bacterial skin and skin structure infections treatment market report, assessing the market on the basis of its segments like infection type, route of administration, treatment channel, and major regions.
The report studies the latest updates in the market, along with their impact across the market. It also analyses the market demand, together with its price and demand indicators. The report also tracks the market on the bases of SWOT and Porter’s Five Forces Models.
The key highlights of the report include:
Market Overview (2016-2031)
- Prevalence Growth Rate (2023-2031): 21% (Plaque Psoriasis Diagnosed Cases)
The growth of the market is primarily driven by the rising prevalence of plaque psoriasis cases. The prevalence of skin infections, such as impetigo, cellulitis, and folliculitis, are on the rise, driven by factors such as poor hygiene, increased exposure to bacteria, and weakened immune systems. This is driving demand for effective treatment options.
Get a Free Sample Report with Table of Contents@ https://www.expertmarketresearch.com/reports/acute-bacterial-skin-and-skin-structure-infections-absssi-treatment-market/requestsample
The increasing prevalence of antibiotic resistance among bacteria is making it more difficult to treat skin infections with traditional antibiotics. This is driving the need for new and more effective treatment options.
Furthermore, the elderly population is more susceptible to skin infections due to factors such as weakened immune systems, chronic diseases, and decreased mobility. This is driving demand for treatment options specifically designed for this population.
Advances in technology are leading to the development of new and more effective treatment options for skin infections, such as topical and oral antibiotics and antibiotic-resistant bacteria treatments.
Read Full Report with Table of Contents@ https://www.expertmarketresearch.com/reports/acute-bacterial-skin-and-skin-structure-infections-absssi-treatment-market
Acute Bacterial Skin and Skin Structure Infections Treatment Industry Definition and Major Segments
Acute bacterial skin and skin structure infections (ABSSSI) treatment market refers to the market for drugs and therapies used to treat bacterial infections that affect the skin and underlying structures such as the subcutaneous tissue, fascia, and muscle. These infections can include impetigo, cellulitis, and folliculitis, and are typically treated with antibiotics and topical creams. The ABSSSI treatment market is a rapidly growing market, driven by the increasing prevalence of bacterial infections and the development of new and more effective treatment options.
Market Breakup by Infection Type
- Hospital Acquired
- Community Acquired
Market Breakup by Route of Administration
Market Breakup by Treatment Channel
Market Breakup by Region
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
Acute Bacterial Skin and Skin Structure Infections Treatment Market Trends
In recent years, several new antibiotics have been approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). These include oritavancin, dalbavancin, and tedizolid, which have been shown to be effective against methicillin-resistant Staphylococcus aureus (MRSA) and other resistant strains of bacteria.
Researchers are also exploring the use of combination therapy, which involves using more than one antibiotic to treat ABSSSI. This approach aims to improve efficacy and reduce the risk of antibiotic resistance.
Pharmaceutical companies are increasingly focusing on developing treatments that are convenient for patients and easy to administer. For example, some ABSSSI treatments are now available in single-dose formulations, which can help improve patient compliance.
Biosimilars are a relatively new class of drugs that are similar to biologic drugs in terms of safety, efficacy, and quality. Several biosimilars have been approved for the treatment of ABSSSI, and more are expected to be developed in the coming years.
Advances in diagnostic techniques have led to the development of rapid and accurate diagnostic methods for ABSSSI. This has made it easier to identify the specific type of bacteria responsible for an infection, which can help guide treatment decisions.
Key Market Players
The major players in the acute bacterial skin and skin structure infections (ABSSSI) treatment market report are:
- Paratek Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Melinta Therapeutics
- AbbVie Inc.
- Sandoz International GmbH
- Glenmark Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Limited
- Aceragen, Inc. (Arrevus, Inc.)
- Accord Healthcare
- Intas Pharmaceuticals
- Fresenius SE & Co. KGaA
- Zydus Lifesciences Limited
The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.
Read More Reports:
Computer Numerical Control Machines Market: https://www.marketwatch.com/press-release/computer-numerical-control-machine-tools-market-size-share-report-and-forecast-2023-2028-2023-04-24?mod=search_headline
Expert Market Research (EMR) is leading market research company with clients across the globe. Through comprehensive data collection and skillful analysis and interpretation of data, the company offers its clients extensive, latest, and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.
EMR customises syndicated reports according to clients’ requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.
Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate and actionable industry intelligence so that they may formulate informed, effective and intelligent business strategies and ensure their leadership in the market.
Company Name: Claight Corporation
Contact Person: Steven Luke, Corporate Sales Specialist – U.S.A.
Toll Free Number: +1-415-325-5166 | +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA